Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy
2015; Springer Science+Business Media; Linguagem: Inglês
10.1007/82_2015_431
ISSN2196-9965
AutoresKimberly A. Kraynyak, Angela M. Bodles-Brakhop, Mark L. Bagarazzi,
Tópico(s)Immunotherapy and Immune Responses
ResumoCancer is a worldwide leading cause of death, and current conventional therapies are limited. The search for alternative preventive or therapeutic solutions is critical if we are going to improve outcomes for patients. The potential for DNA vaccines in the treatment and prevention of cancer has gained great momentum since initial findings almost 2 decades ago that revealed that genetically engineered DNA can elicit an immune response. The combination of adjuvants and an effective delivery method such as electroporation is overcoming past setbacks for naked plasmid DNA (pDNA) as a potential preventive or therapeutic approach to cancer in large animals and humans. In this chapter, we aim to focus on the novel advances in recent years for DNA cancer vaccines, current preclinical data, and the importance of adjuvants and electroporation with emphasis on prostate, melanoma, and cervical cancer.
Referência(s)